Comparison of the Hypophosphatasemic Effects of Erythropoietin and U-74389G on Acid Phosphatase Levels

C Τsompos¹*, C Panoulis^, K Τοutouzas³, A Triantafyllou⁴, CG Ζografos³, K Tsarea⁵, M Karamperi⁵ and A Papalois⁵

Received: January 28, 2019;   Published: February 05, 2018

DOI: 10.32474/OSMOAJ.2019.02.000142

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Aim: This study calculated the effects on acid phosphatase (ACP) levels, after treatment with either of 2 drugs: the erythropoietin (Epo) and the antioxidant lazaroid (L) drug U-74389G. The calculation was based on the results of 2 preliminary studies, each one of which estimated the certain influence, after the respective drug usage in an induced ischemia reperfusion (IR) animal experiment.

Materials and Methods: The 2 main experimental endpoints at which the serum ACP levels (ACPl) were evaluated was the 60th reperfusion min (for the groups A, C and E) and the 120th reperfusion min (for the groups B, D and F). Specially, the groups A and B were processed without drugs, groups C and D after Epo administration; whereas groups E and F after the L administration.

Results: The first preliminary study of Epo presented a non-significant hypophosphatasemic effect by 9.29%+6.36% (p-value=0.1396). The second preliminary study of U-74389G presented a significant hypophosphatasemic effect by 74.46%+9.63% (p-value=0.0000). These 2 studies were co-evaluated since they came from the same experimental setting. The outcome of the coevaluation was that L is 8.011334-fold [7.996741 - 8.025953] more hypophosphatasemic than Epo (p-value=0.0000).

Conclusion: The anti-oxidant capacities of U-74389G ascribe 8.011334-fold more hypophosphatasemic effects than Epo (p-value=0.0000).

Keywords:Ischemia; Erythropoietin; U-74389G; Acid Phosphatase Levels; Reperfusion

Abstract| Introduction| Materials & Methods| Results| Discussion| Conclusion| References|